Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:SYK
Stryker Corp. (SYK)
307.00
-0.80 (0.26%)
as of Jun 18, 2026, 8:52:16 pm Market Open.
184 watching
Financials 
Technical Analysis 0
PAST TOP PICK
(A Top Pick Mar 29/21, Up 10%) Company was impacted by Covid-19 (elective procedures reduced).
As pandemic recedes, business will improve.
Expecting, A&D, further acquisitions and continued growth.
Trading at 26x earnings (P/E) which is a fair valuation.
Would buy more shares and hold.
biotechnologypharmaceutical
TOP PICK
Pandemic cancelled elective surgeries, backlog now clearing. Population is aging, and surgeries benefit quality of life. Brand loyalty among physicians. Geographical growth. Recent acquisition will increase digitization of products, which will help patient care. Will see uptick in revenue. Great valuation here. Yield is 1.06%. (Analysts’ price target is $281.30)
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Feb 11/21, Up 4%) Came under pressure, as it's classified higher growth. Still likes their business, as everything in those operating rooms is made by Stryker. Main area of growth is robotic surgery. Wage and cost inflation. Sees perhaps slower capex. Very well run.
Paul MacDonaldOwned
biotechnologypharmaceutical
TOP PICK
73% of their business is in the US plus 21% in developed markets and 6% in emerging, so there's more EM growth to come. Also, elective surgeries were put on hold during Covid, so there's a big backlog to come. Also aging demographics are a tailwind. Also, surgeons remain loyal to their surgical products. (Analysts’ price target is $284.10)
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Oct 02/20, Up 34%) This was recommend before vaccines. This company benefits from elective surgery. These surgeries were not happening then. Expects them to report record earnings in 2021. Better days lie a head. Benefits from the aging population. Has intimate relationships with doctors. It is also a platform that is good at acquiring businesses.
Barry SchwartzOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Sep 14/20, Up 32%) Medical devices are an important place to be. Good acquisition right before the pandemic. Demographic play. Pandemic backlog should ease and improve revenues. Good opportunity globally for next few years.
Paul Harris, CFAOwned
biotechnologypharmaceutical
TOP PICK
Has long held this. They produce medical devices for hips, knees and spines. The sector fell off during lockdowns due to no or few elective surgeries, however that is rebounding. Also, this is a demographic play as the population ages and needs such surgeries. Also, doctors stay loyal to a brand of medical devices. Trades at 25x earnings and has $3.7 billion in free cash. (Analysts’ price target is $288.43)
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Jul 21/20, Up 37%) Great business. Demographic tailwind. User loyalty. Pandemic surgery slowdown created a backlog that's coming online now. Good free cashflow growth can be used to pay down debt and make acquisitions. Good upside for next several years.
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Jun 26/20, Up 50%) Huge backlog of surgeries due to Covid. Really improves quality of life. Terrific brand loyalty. Good demographic play. More upside. Will keep raising dividend, buying back shares, making acquisitions.
Paul Harris, CFAOwned
biotechnologypharmaceutical
BUY
With the opening of elective surgeries, it will start to pickup. The aging population will benefit them. They are head and shoulders above their peers.
David DriscollOwned
biotechnologypharmaceutical
TOP PICK
Rough time, as elective surgeries on hold during Covid. Good growth. Loyal users of products, good demographics. Acquisition of Wright Medical will work out well. Yield is 1.02%. (Analysts’ price target is $270.28)
Paul Harris, CFAOwned
biotechnologypharmaceutical
BUY
Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.
David BurrowsOwned
biotechnologypharmaceutical
TOP PICK
They produce medical devices for hips, knees, hands and ankles. Elective surgeries are coming back after pandemic lockdowns. SYK's medical products reduce medical stays and drug use, which benefits American hospitals and patients. Again demographics are another tailwind. He expects good growth. SYK holds a lot of fresh cash to pay debt and the dividend. (Analysts’ price target is $251.00)
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Jan 17/20, Up 16%) Medical devices and robotic-assisted surgery. Elective surgeries have resumed from last quarter.
Paul MacDonaldOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
